A high-throughput screening assay for assessing the viability of Cryptococcus neoformans under nutrient starvation conditions
- 296 Downloads
Cryptococcus neoformans causes an estimated 600,000 AIDS-related deaths annually that occur primarily in resource-limited countries. Fluconazole and amphotericin B are currently available for the treatment of cryptococcal-related infections. However, fluconazole has limited clinical efficacy and amphotericin B requires intravenous infusion and is associated with high renal toxicity. Therefore, there is an unmet need for a new orally administrable anti-cryptococcal drug. We have developed a high-throughput screening assay for the measurement of C. neoformans viability in 1,536-well plate format. The signal-to-basal ratio of the ATP content assay was 21.9 fold with a coefficient of variation and Z' factor of 7.1 % and 0.76, respectively. A pilot screen of 1,280 known compounds against the wild-type C. neoformans (strain H99) led to the identification of four active compounds including niclosamide, malonoben, 6-bromoindirubin-3′-oxime, and 5-[(4-ethylphenyl)methylene]-2-thioxo-4-thiazolidinone. These compounds were further tested against nine clinical isolates of C. neoformans, and their fungicidal activities were confirmed. The results demonstrate that this miniaturized C. neoformans assay is advantageous for the high-throughput screening of large compound collections to identify lead compounds for new anti-cryptococcal drug development.
KeywordsCryptococcus neoformans Cryptococcal infections Cryptococcal meningitis High-throughput screening ATP content assay
This work was supported by the Intramural Research Programs of the Therapeutics for Rare and Neglected Diseases, National Center for Advancing Translational Sciences (NCATS), and National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH). The authors thank Paul Shinn and compound management team at NCATS for their assistance.
- 2.Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, Bekker LG, Harrison T (2007) Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 45(1):76–80CrossRefGoogle Scholar
- 3.Rabjohns JLA, Park YD, Dehdashti J, Zheng W, Williamson PR (2013) A high throughput screening assay for fungicidal compounds against Cryptococcus neoformans. J Biomol Screen (in press)Google Scholar
- 6.Coconnier-Polter MH, Lievin-Le Moal V, Servin AL (2005) A Lactobacillus acidophilus strain of human gastrointestinal microbiota origin elicits killing of enterovirulent Salmonella enterica Serovar Typhimurium by triggering lethal bacterial membrane damage. Appl Environ Microbiol 71(10):6115–6120CrossRefGoogle Scholar
- 8.Kim K, Pollard JM, Norris AJ, McDonald JT, Sun Y, Micewicz E, Pettijohn K, Damoiseaux R, Iwamoto KS, Sayre JW, Price BD, Gatti RA, McBride WH (2009) High-throughput screening identifies two classes of antibiotics as radioprotectors: tetracyclines and fluoroquinolones. Clin Cancer Res 15(23):7238–7245CrossRefGoogle Scholar
- 13.Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU, Fisher JF et al (1992) Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 326(2):83–89CrossRefGoogle Scholar
- 14.Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN (2011) Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. Diagn Microbiol Infect Dis 71(3):252–259CrossRefGoogle Scholar
- 20.Butts A, Didone L, Koselny K, Baxter BK, Chabrier-Rosello Y, Wellington M, Krysan DJ (2013) A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. Eukaryot Cell 12(2):278–287CrossRefGoogle Scholar